Support 100 years of independent journalism.

  1. Business
14 May 2012

Other people’s business, Monday 13 April

Jewellers and Yahoo!

By New Statesman

1. Jewellers needed to ease gold bugs’ pain (Reuters)

Gold has a dual personality, writes Kevin Allison.

2. Yahoo! sheds another boss: Degree of pain (Schumpeter)

Critics of Yahoo! had hoped that when Scott Thompson took over the helm of the web giant in January, he would bring some badly needed stability to a business that had been struggling for years to turn itself around, writes Schumpeter.

3. Self-medication: When waiting is not an option (Babbage)

Sign up for The New Statesman’s newsletters Tick the boxes of the newsletters you would like to receive. Quick and essential guide to domestic and global politics from the New Statesman's politics team. The best of the New Statesman, delivered to your inbox every weekday morning. The New Statesman’s global affairs newsletter, every Monday and Friday. A handy, three-minute glance at the week ahead in companies, markets, regulation and investment, landing in your inbox every Monday morning. Our weekly culture newsletter – from books and art to pop culture and memes – sent every Friday. A weekly round-up of some of the best articles featured in the most recent issue of the New Statesman, sent each Saturday. A weekly dig into the New Statesman’s archive of over 100 years of stellar and influential journalism, sent each Wednesday. Sign up to receive information regarding NS events, subscription offers & product updates.
I consent to New Statesman Media Group collecting my details provided via this form in accordance with the Privacy Policy

It takes eight years on average for a drug to receive approval from America’s Food and Drug Administration (FDA) after clinical trials have been successfully completed, writes Babbage.

4. Pricey Chesapeake medicine highlights its sickness (Reuters)

Pricey medicine can help, writes Christopher Swann and Robert Cyran.

5. JPMorgan’s trading mistakes: A billion here, a billion there (Schumpeter)

JP Morgan, widely considered the best run of all the large banks in America, if not the world, on May 10th provided the kind of news that has become all too common in the financial industry: a $2 billion charge for errant trades, writes Schumpeter.